Amyotrophic Lateral Sclerosis & Frontotemporal Dementia
An ischemic stroke happens when blood flow to part of the brain is suddenly blocked, usually by a clot or artery-narrowing debris. Because brain tissue depends on a constant supply of oxygen and glucose, even a short interruption can quickly injure or kill neurons. Ischemic strokes make up the large majority of all strokes, and they are a true medical emergency because treatment is most effective when it happens fast.
Stroke can affect adults across a wide age range, but risk rises sharply with age and with vascular risk factors such as high blood pressure, diabetes, smoking, obesity, high cholesterol, atrial fibrillation, and physical inactivity. Symptoms often appear suddenly and can include facial drooping, arm weakness, speech difficulty, vision changes, or loss of balance. The reason these symptoms vary so much is that different brain regions control different functions, so the effects depend on where the blockage occurs.
The first phase is the acute vascular event, when blood flow is lost and tissue is immediately threatened. The second phase is the downstream neurological aftermath, where inflammation, axon injury, circuit disruption, and progressive tissue loss can continue long after the original clot is gone. That second phase is where stroke begins to overlap more clearly with neurodegeneration.
Pathology
The first biological problem in ischemic stroke is energy failure. When blood flow stops, neurons and glia (the cells that surround and support neurons) lose access to oxygen and glucose, which means they can no longer make enough ATP to function normally. Ion gradients collapse, cells depolarize, and excessive glutamate release can trigger excitotoxicity, a damaging state in which overstimulated neurons take in toxic amounts of calcium and become further injured.
Stroke tissue is often described as having a core and a penumbra. In the core, blood flow is so severely reduced that cells die quickly. In the surrounding penumbra, tissue is impaired but not yet irreversibly lost, which is why rapid treatment matters so much. Saving penumbral tissue is one of the main goals of emergency stroke care, including thrombolysis and mechanical clot removal when patients are eligible.
After the initial event, injury does not simply stop. The damaged area can trigger inflammation, blood-brain barrier disruption, white matter injury, and degeneration of connected pathways that were not part of the original infarct. Over time, this contributes to cognitive decline, persistent disability, and loss of brain tissue beyond the first lesion. That is why ischemic stroke is not only a “moment” of injury, but often the beginning of a longer disease process.
Biological Pathways
One key pathway is excitotoxic and metabolic injury. Once circulation falls, cells switch into a crisis mode where energy production fails, calcium handling worsens, and oxidative stress rises. This sets off a damaging biochemical cascade that can continue even if blood flow is later restored.
A second major pathway is inflammation. Immune signaling is part of the brain’s response to injury, but it can become a double-edged sword. In the early period after stroke, inflammatory cells and mediators can enlarge injury, damage nearby tissue, and disrupt the blood-brain barrier. Over longer periods, ongoing inflammatory changes may contribute to chronic tissue remodeling and cognitive decline.
A third important pathway is white matter and axon degeneration. Stroke does not only kill neurons in gray matter. It can also injure myelinated axons and long brain connections, which matters greatly for lasting function. This is one place where SARM1 may be relevant. SARM1 is best known as an executioner of programmed axon degeneration, and recent preclinical work suggests that loss of SARM1 can reduce axonal degeneration and improve outcomes in experimental ischemic injury models. That makes it an interesting mechanistic target, especially for the longer-lasting degenerative component of stroke, though it is not part of standard patient care today.
Causes
Ischemic strokes are caused by an artery that supplies the brain becoming blocked. The blockage may come from a clot forming directly in a vessel supplying the brain, a clot traveling from the heart or a more distant artery, or plaque-related narrowing that reduces or interrupts blood flow. Common clinical causes include large artery atherosclerosis, small vessel disease, and cardioembolic stroke, especially from atrial fibrillation.
The major risk factors are largely vascular. High blood pressure is one of the most important, but diabetes, smoking, high cholesterol, obesity, inactivity, and heart rhythm disorders also contribute substantially. Because many of these are modifiable, stroke prevention is one of the clearest examples in neurology of how risk-factor control can directly reduce disease burden.
Genetics can influence stroke susceptibility in some individuals, but for most patients the stronger drivers are age, vascular health, and cardiac risk. In other words, ischemic stroke is usually not inherited in the same direct way as Huntington’s disease, even though family history can still shape overall risk through shared biology and shared lifestyle patterns.
Progression
Stroke progression has to be understood on two timescales. In the acute phase, symptoms may worsen over minutes to hours if the blocked territory expands, the penumbra is not rescued, swelling develops, or complications occur. This is why rapid emergency evaluation is so important. The early treatment window can strongly influence how much brain tissue is ultimately saved.
After that, recovery and decline can happen at the same time. Many patients improve because swelling decreases, surviving circuits adapt, and rehabilitation helps the brain relearn lost functions. But some also develop longer-term problems related to persistent white matter injury, remote degeneration in connected regions, chronic inflammation, or vascular cognitive impairment.
This is an important distinction from diseases like Alzheimer’s or Parkinson’s. Stroke begins with a sudden event, but the neurological consequences can continue evolving for months or years. In some patients, post-stroke degeneration becomes a major part of the long-term burden.
Treatment Landscape
The treatment landscape for acute ischemic stroke has improved substantially, but it is still highly time-dependent. The main goals in the emergency setting are to recognize stroke quickly, confirm the diagnosis, and restore blood flow. Current guideline-supported acute treatments include thrombolytic therapy in eligible patients and mechanical thrombectomy for selected large-vessel occlusions.
After the acute phase, treatment shifts toward secondary prevention and recovery. Secondary prevention can include blood pressure control, lipid lowering, antiplatelet or anticoagulant strategies depending on the cause, smoking cessation, and management of diabetes or heart disease. Rehabilitation is equally important, because recovery depends not only on what tissue was saved, but on how well patients can rebuild function through physical, occupational, speech, and cognitive therapy.
Where current treatment still falls short is in directly targeting the chronic neurodegenerative aftermath of stroke. We are much better at reopening blocked vessels than at protecting axons, preventing remote degeneration, or restoring damaged white matter once the acute crisis has passed. That gap is one reason there is growing interest in neuroprotective and axon-protective pathways, including SARM1, though these remain research-stage.
Research Directions
One major research direction is improving neuroprotection: helping vulnerable tissue survive during and after ischemia rather than focusing only on reperfusion. This includes studying metabolic resilience, inflammation, white matter protection, and better matching therapies to stroke subtype and timing.
A second direction is understanding chronic post-stroke pathology. Researchers are increasingly focused on why some patients experience ongoing cognitive decline, white matter deterioration, or poor recovery even after the initial infarct has stabilized. Imaging markers, inflammation measures, and network-level studies are helping define this later phase more clearly.
A third direction is the push toward axon and circuit preservation. This is where SARM1 enters the picture. The evidence is still preclinical, but recent studies suggest that interrupting axon degeneration pathways after ischemic injury may preserve white matter and improve functional recovery.